CD70, AlpHcAbs® Human Alpaca Monoclonal Antibody (HA710335)
Catalog# HA710335
Alpaca Monoclonal to CD70, AlpHcAbs® Human
Tested for
-
ELISA
-
FC
Reacts with
-
Human
Advantages of using an Alpaca Recombinant Secondary
1. Smaller size
Nanobodies are 1/10 the size of a traditional antibody (~15 kDa unconjugated). This means that the nanobody can penetrate tissue faster and deeper than other antibodies.
2. Easier to use
Due to their simple structure, nanobodies also have the advantage of increased stability and ease of use.
3. Easier production
When compared to a more traditional antibody, nanobodies are easier to develop and produce in the lab than monoclonal or polyclonal antibodies.
4. More consistent
Since nanobodies are recombinantly produced from clonal DNA, you are guaranteed the same product every time. Comparatively, polyclonal antibodies are produced in live animals and have a very low lot-to-lot consistency while monoclonal antibodies can suffer from drift.
5. Higher Affinity
Nanobodies benefit from consistently high binding affinity values.
1. Smaller size
Nanobodies are 1/10 the size of a traditional antibody (~15 kDa unconjugated). This means that the nanobody can penetrate tissue faster and deeper than other antibodies.
2. Easier to use
Due to their simple structure, nanobodies also have the advantage of increased stability and ease of use.
3. Easier production
When compared to a more traditional antibody, nanobodies are easier to develop and produce in the lab than monoclonal or polyclonal antibodies.
4. More consistent
Since nanobodies are recombinantly produced from clonal DNA, you are guaranteed the same product every time. Comparatively, polyclonal antibodies are produced in live animals and have a very low lot-to-lot consistency while monoclonal antibodies can suffer from drift.
5. Higher Affinity
Nanobodies benefit from consistently high binding affinity values.